Cingulate to Present at H.C. Wainwright Global Investment Conference

KANSAS Town, Kan., Could 18, 2022 (Globe NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a clinical-phase biopharmaceutical firm making use of its proprietary Precision Timed Release™ (PTR™) drug shipping platform technological innovation to build and advance a pipeline of up coming-generation pharmaceutical merchandise, now declared that Chairman and Main Govt Officer, Shane J. Schaffer, and Main Health-related Officer, Matthew Brams, M.D., will present a organization overview at the H.C. Wainwright Worldwide Financial investment Conference on Wednesday, May well 25, 2022, from 3:00-3:30 p.m. ET, at the Fontainebleau Miami Beach Resort, Miami, FL.

A are living webcast of the presentation might be accessed at: HCW – Cingulate Dwell Presentation. A replay will be out there on the trader area of Cingulate’s internet site at Cingulate Functions & Displays for 90 times.

About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a clinical-phase biopharmaceutical company using its proprietary Precision Timed Release™ (PTR™) drug shipping and delivery platform technologies to develop and advance a pipeline of up coming-era pharmaceutical products, designed to improve the life of people struggling from frequently diagnosed ailments characterized by burdensome each day dosing regimens and suboptimal cure results. With an original focus on the treatment method of Consideration Deficit/Hyperactivity Dysfunction (ADHD), Cingulate is determining and assessing supplemental therapeutic places the place PTR technological know-how may be utilized to acquire foreseeable future merchandise candidates, these types of as panic problems.

Cingulate is headquartered in Kansas Town, KS. For additional facts visit Cingulate.com

Investor Relations 
Thomas Dalton
Head of Trader & Community Relations, Cingulate, Inc.
(913) 942-2301
[email protected]

Matt Kreps
Darrow Associates
(214) 597-8200
[email protected]

Media Relations
Melyssa Weible
Elixir Health and fitness General public Relations
(201) 723-5805
[email protected]